Disclosure Of Interests In Other Entities [Text Block]

Hyloris Pharmaceuticals SA - Filing #3166143

Concept	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31
Disclosure of interests in other entities [text block]	—	—	—	—	—	—	—	—
Disclosure of interests in subsidiaries [text block]	—	—	—	—	—	—	—	—
Disclosure of subsidiaries [text block]	6. LIST OF CONSOLIDATED COMPANIES AS AT DECEMBER 31, 2023	—	—	—	—	—	—	—
Disclosure of subsidiaries [abstract]
Disclosure of subsidiaries [line items]
Current assets	—	35,308,000 EUR	—	—	—	49,801,000 EUR	—	—
Non-current assets	—	12,373,000 EUR	—	—	—	10,927,000 EUR	—	—
Current liabilities	—	6,759,000 EUR	—	—	—	5,772,000 EUR	—	—
Non-current liabilities	—	1,853,000 EUR	—	—	—	1,047,000 EUR	—	—
Revenue	2,087,000 EUR	—	—	—	—	—	900,000 EUR	—
Profit (loss)	15,380,000 EUR	—	—	—	—	—	11,906,000 EUR	—
Comprehensive income	15,380,000 EUR	—	15,380,000 EUR	10,770,000 EUR	10,770,000 EUR	—	11,906,000 EUR	—
Disclosure of interests in associates [text block]	—	—	—	—	—	—	—	—
Disclosure of associates [text block]	—	—	—	—	—	—	—	—
Disclosure of associates [abstract]
Disclosure of associates [line items]
Other comprehensive income	- EUR	—	—	—	—	—	- EUR	—
Investments accounted for using equity method	—	3,801,000 EUR	—	—	—	3,948,000 EUR	—	—
Disclosure of interests in joint arrangements [text block]	—	—	—	—	—	—	—	—
Disclosure of joint operations [text block]	3	—	—	—	—	—	—	—
Disclosure of joint ventures [text block]	—	—	—	—	—	—	—	—
Disclosure of joint ventures [abstract]
Disclosure of joint ventures [line items]
Cash and cash equivalents	—	30,406,000 EUR	—	—	—	33,457,000 EUR	—	50,012,000 EUR
Other current financial liabilities	—	3,200,000 EUR	—	—	—	3,212,000 EUR	—	—
Other non-current financial liabilities	—	344,000 EUR	—	—	—	300,000 EUR	—	—
Tax expense (income)	- EUR	—	—	—	—	—	4,000 EUR	—